Metformin Treatment Reduces CRC Aggressiveness in a Glucose-Independent Manner: An In Vitro and Ex Vivo Study

(1) Background: Metformin, an anti-diabetic drug, seems to protect against aggressive acquisition in colorectal cancers (CRCs). However, its mechanisms are still really unknown, raising questions about the possibility of its positive impact on non-diabetic patients with CRC. (2) Methods: An study ba...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-07, Vol.15 (14), p.3724
Main Authors: Boutaud, Marie, Auger, Clément, Verdier, Mireille, Christou, Niki
Format: Article
Language:English
Subjects:
Cell activation
Cell growth
Colon cancer
Colorectal carcinoma
Diabetes mellitus (non-insulin dependent)
E-cadherin
Extracellular matrix
Gelatinase A
Gelatinase B
Glucose
Kinases
Metformin
Ovarian cancer
Patients
Phosphates
Proteomics
Transcriptomics
Tumor cell lines
Tumorigenesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:(1) Background: Metformin, an anti-diabetic drug, seems to protect against aggressive acquisition in colorectal cancers (CRCs). However, its mechanisms are still really unknown, raising questions about the possibility of its positive impact on non-diabetic patients with CRC. (2) Methods: An study based on human colon cancer cell lines and an study with different colon cancer stages with proteomic and transcriptomic analyses were initiated. (3) Results: Metformin seems to protect from colon cancer invasive acquisition, irrespective of glucose concentration. (4) Conclusions: Metformin could be used as an adjuvant treatment to surgery for both diabetic and non-diabetic patients in order to prevent the acquisition of aggressiveness and, ultimately, recurrences.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15143724